291289-27-5

Upstream product

• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6457-49-4 4-piperidinemethanol 

Downstream Products

• 914654-67-4 Methyl 2-{[3-({1-[(1,1-Dimethylethoxy)carbonyl]piperidin-4-yl}methyl)-2-phenylquinolin-4-yl]carbonyl}-1-phenylhydrazinecarboxylate 
• 914654-66-3 3-({1-[(1,1-dimethylethoxy)carbonyl]piperidin-4-yl}methyl)-N',2-diphenylquinoline-4-carbohydrazide 
• 914654-70-9 methyl 2-({3-[(piperidin-4-yl)methyl]-2-phenylquinolin-4-yl}carbonyl)-1-phenylhydrazinecarboxylate 
• 914654-64-1 3-{1-[(1,1-dimethylethoxy)carbonyl]piperidin-4-yl}methyl-2-phenylquinoline-4-carboxylic acid 
• 301232-43-9 tert-butyl 4-(3-oxo-3-phenylpropyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II

Introduction of selected amine containing side chains into the 3-position of N′,2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hIKr affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ90 7 mg/kg po; plasma Occ90 0.4 μM) and has good selectivity and excellent PK properties.